Skip to main content

Table 1 Demographic and baseline characteristics by GOLD stage*

From: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

Variable

Stage IV

(< 30% predicted)

(n = 937)

Stage III

(30% to < 50% predicted)

(n = 3019)

Stage II

(≥ 50% predicted)

(n = 2156)

Total population

(n = 6112)

age, mean (years)

64.2 ± 7.8

65.4 ± 8.1

64.9 ± 8.7

65.0 ± 8.3

male (%)

83

76

72

76

BMI, mean (kg/m2)

23.5 ± 4.9

25.1 ± 5.0

26.6 ± 5.2

25.4 ± 5.2

smoking status: current (%)

34

43

47

43

exacerbations

    

   number requiring antibiotics and/or oral corticosteroids, mean

1.3 ± 1.5

1.0 ± 1.4

0.9 ± 1.2

1.0 ± 1.3

   number requiring hospitalization, mean

0.4 ± 0.7

0.3 ± 0.7

0.2 ± 0.5

0.2 ± 0.6

post-bronchodilator FEV1, mean (ml)

704 ± 160

1108 ± 263

1616 ± 399

1226 ± 443

% predicted post-bronchodilator FEV1, mean

24.6 ± 4.0

40.1 ± 5.7

58.8 ± 7.4

44.3 ± 13.4

SGRQ score, mean

(n = 730)

(n = 2460)

(n = 1761)

(n = 4951)

   total score

56.5 ± 15.0

50.0 ± 16.5

45.4 ± 17.7

49.3 ± 17.1

   symptoms score

67.0 ± 18.0

63.5 ± 19.3

60.3 ± 21.0

62.9 ± 19.9

   activity score

73.4 ± 16.7

64.1 ± 19.0

57.1 ± 20.6

63.0 ± 20.0

   impact score

43.6 ± 18.6

37.7 ± 18.8

33.6 ± 19.6

37.1 ± 19.3

reversibility as % of predicted FEV1, mean

2.5 ± 3.2

3.6 ± 3.6

4.3 ± 4.0

3.7 ± 3.7

  1. *Plus-minus values are mean ± standard deviation